Oxana Ibraghimov-Beskrovnaya

Summary

Affiliation: Genzyme Corporation
Country: USA

Publications

  1. ncbi request reprint In vitro cystogenesis: the search for drugs antagonizing cyst development
    Oxana Ibraghimov-Beskrovnaya
    Genzyme Corporation, 5, Mountain Road, Framingham, MA 01701 9322, Etats Unis
    Nephrol Ther 2:S109-14. 2006
  2. doi request reprint mTOR signaling in polycystic kidney disease
    Oxana Ibraghimov-Beskrovnaya
    Cell Biology, Genzyme Corporation, 49 New York Avenue, Framingham, MA, USA
    Trends Mol Med 17:625-33. 2011
  3. pmc Polycystic kidney diseases: from molecular discoveries to targeted therapeutic strategies
    O Ibraghimov-Beskrovnaya
    Cell Biology, Genzyme Corporation, 5 Mountain Road, Framingham, MA 01701 9322, USA
    Cell Mol Life Sci 65:605-19. 2008
  4. ncbi request reprint Targeting dysregulated cell cycle and apoptosis for polycystic kidney disease therapy
    Oxana Ibraghimov-Beskrovnaya
    Genzyme Corporation, Framingham, Massachusetts 01701, USA
    Cell Cycle 6:776-9. 2007
  5. ncbi request reprint Pkd1 and Nek8 mutations affect cell-cell adhesion and cilia in cysts formed in kidney organ cultures
    Thomas A Natoli
    Department of Cell Biology, Genzyme Corporation, 5 Mountain Rd, Framingham, MA 01701 9322, USA
    Am J Physiol Renal Physiol 294:F73-83. 2008
  6. pmc Loss of GM3 synthase gene, but not sphingosine kinase 1, is protective against murine nephronophthisis-related polycystic kidney disease
    Thomas A Natoli
    Department of Cell Biology, Genzyme Corporation, Framingham, MA 01701, USA
    Hum Mol Genet 21:3397-407. 2012
  7. ncbi request reprint Functional polycystin-1 expression is developmentally regulated during epithelial morphogenesis in vitro: downregulation and loss of membrane localization during cystogenesis
    Nikolay O Bukanov
    Genzyme Corporation, 5 Mountain Road, Framingham, MA 01701 9322, USA
    Hum Mol Genet 11:923-36. 2002
  8. ncbi request reprint Development of polycystic kidney disease in juvenile cystic kidney mice: insights into pathogenesis, ciliary abnormalities, and common features with human disease
    Laurie A Smith
    Genzyme Corporation, 5 Mountain Road, Framingham, MA 01701 9322, USA
    J Am Soc Nephrol 17:2821-31. 2006
  9. pmc Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models
    Thomas A Natoli
    Department of Cell Biology, Genzyme Corporation, Framingham, Massachusetts, USA
    Nat Med 16:788-92. 2010
  10. pmc CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD
    Nikolay O Bukanov
    Cell Biology, Genzyme, a Sanofi Company, Framingham, MA, USA
    Cell Cycle 11:4040-6. 2012

Collaborators

  • Bing Wang
  • Dominique Joly
  • Viatcheslav R Akmaev
  • Laurie Smith
  • Seth L Alper
  • A C Ong
  • Michael Caplan
  • Thomas Hiesberger
  • Peter Igarashi
  • Nikolay O Bukanov
  • Thomas A Natoli
  • Herve Husson
  • Ryan J Russo
  • Steven R Ledbetter
  • Katherine W Klinger
  • William R Dackowski
  • Kelly A Rogers
  • John P Leonard
  • Yeva Budman
  • Bruce L Roberts
  • Sarah Moreno
  • Veronique Chauvet
  • Partha Manavalan
  • Andrew J Streets
  • David H Vandorpe
  • Sarah E Moreno
  • HervĂ© Galons
  • Laurent Meijer
  • Nassima Oumata
  • Svetlana Komarnitsky
  • Alexei Belenky
  • James A Shayman
  • Douglas Matthews
  • Peter Piepenhagen
  • Tiffany C Gareski
  • Natacha Patey
  • Bertrand Knebelmann
  • Dongyu Liu
  • Douglas M Jefferson
  • Tong Wang
  • David H Grimm
  • Xiaohong Cao
  • Stefan Somlo
  • Xin Tian
  • Thomas Hieseberger
  • Anton M Bennett
  • Dana Barberio
  • Brian Cook
  • Shelley A Grubman
  • Gregory M Landes
  • Brenda Richards
  • Clarence J Wang
  • Linda J Newby
  • Michael J O'Hare
  • Brandon D Lawrence
  • Alan K Stuart-Tilley
  • Hilary F Luderer
  • Sabine Wilhelm
  • Marina N Chernova
  • Lianwei Jiang
  • Patricia A Clow

Detail Information

Publications19

  1. ncbi request reprint In vitro cystogenesis: the search for drugs antagonizing cyst development
    Oxana Ibraghimov-Beskrovnaya
    Genzyme Corporation, 5, Mountain Road, Framingham, MA 01701 9322, Etats Unis
    Nephrol Ther 2:S109-14. 2006
    ..We have used in vitro cystogenesis assay for a high throughput screen of small molecule drugs and identified drugs specifically inhibiting cystogenesis but not tubulogenesis in vitro...
  2. doi request reprint mTOR signaling in polycystic kidney disease
    Oxana Ibraghimov-Beskrovnaya
    Cell Biology, Genzyme Corporation, 49 New York Avenue, Framingham, MA, USA
    Trends Mol Med 17:625-33. 2011
    ..We discuss the mTOR pathway in depth, highlighting recent progress in understanding its role in PKD and the current results of clinical trials...
  3. pmc Polycystic kidney diseases: from molecular discoveries to targeted therapeutic strategies
    O Ibraghimov-Beskrovnaya
    Cell Biology, Genzyme Corporation, 5 Mountain Road, Framingham, MA 01701 9322, USA
    Cell Mol Life Sci 65:605-19. 2008
    ..We discuss available models and challenges for therapeutic discovery as well as summarize the results from preclinical experimental treatments targeting key disease-specific pathways...
  4. ncbi request reprint Targeting dysregulated cell cycle and apoptosis for polycystic kidney disease therapy
    Oxana Ibraghimov-Beskrovnaya
    Genzyme Corporation, Framingham, Massachusetts 01701, USA
    Cell Cycle 6:776-9. 2007
    ..Thus, therapies directly targeting coordinate regulation of proliferation and apoptosis are emerging as effective approaches to treat multiple renal diseases...
  5. ncbi request reprint Pkd1 and Nek8 mutations affect cell-cell adhesion and cilia in cysts formed in kidney organ cultures
    Thomas A Natoli
    Department of Cell Biology, Genzyme Corporation, 5 Mountain Rd, Framingham, MA 01701 9322, USA
    Am J Physiol Renal Physiol 294:F73-83. 2008
    ..Therefore, embryonic kidney organ culture represents a relevant model for studying molecular cystogenesis and a rapid tool for the screening for therapies that block cystic growth...
  6. pmc Loss of GM3 synthase gene, but not sphingosine kinase 1, is protective against murine nephronophthisis-related polycystic kidney disease
    Thomas A Natoli
    Department of Cell Biology, Genzyme Corporation, Framingham, MA 01701, USA
    Hum Mol Genet 21:3397-407. 2012
    ..Together, these data suggest that genes involved in the SL metabolism may be modifiers of cystogenesis, and suggest GM3 synthase as a new anti-cystic therapeutic target...
  7. ncbi request reprint Functional polycystin-1 expression is developmentally regulated during epithelial morphogenesis in vitro: downregulation and loss of membrane localization during cystogenesis
    Nikolay O Bukanov
    Genzyme Corporation, 5 Mountain Road, Framingham, MA 01701 9322, USA
    Hum Mol Genet 11:923-36. 2002
    ..We suggest that the loss of polycystin-1 from its basolateral location in tubular epithelium may alter critical pathways controlling normal tubulogenesis leading to cystic transformation...
  8. ncbi request reprint Development of polycystic kidney disease in juvenile cystic kidney mice: insights into pathogenesis, ciliary abnormalities, and common features with human disease
    Laurie A Smith
    Genzyme Corporation, 5 Mountain Road, Framingham, MA 01701 9322, USA
    J Am Soc Nephrol 17:2821-31. 2006
    ..Collectively, these data demonstrate that the jck mice should be useful for testing potential therapies and for studying the molecular mechanisms that link ciliary structure/function and cystogenesis...
  9. pmc Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models
    Thomas A Natoli
    Department of Cell Biology, Genzyme Corporation, Framingham, Massachusetts, USA
    Nat Med 16:788-92. 2010
    ..Taken together, our data suggest that inhibition of GlcCer synthesis represents a new and effective treatment option for PKD...
  10. pmc CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD
    Nikolay O Bukanov
    Cell Biology, Genzyme, a Sanofi Company, Framingham, MA, USA
    Cell Cycle 11:4040-6. 2012
    ..Mechanism of action studies demonstrated effective blockade of cell cycle and proliferation and reduction of apoptosis. Together, these data validate CDK inhibition as a novel and effective approach for the treatment of ADPKD...
  11. ncbi request reprint Serum and urinary biomarker signatures for rapid preclinical in vivo assessment of CDK inhibition as a therapeutic approach for PKD
    Sarah Moreno
    Cell Biology, Genzyme Corporation, Framingham, Massachusetts 01701 9322, USA
    Cell Cycle 7:1856-64. 2008
    ..This biomarker signature provides a necessary tool for further assessment of CDK inhibitors as therapeutic agents for PKD...
  12. ncbi request reprint Canine PKD1 is a single-copy gene: genomic organization and comparative analysis
    William R Dackowski
    Genzyme Corporation, 5 Mountain Road, Framingham, Massachusetts, 01701 9322, USA
    Genomics 80:105-12. 2002
    ..These data enable detailed analysis of the role of polycystin-1 in cystogenesis and tubulogenesis using the canine MDCK cell line...
  13. ncbi request reprint Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine
    Nikolay O Bukanov
    Cell Biology, Genzyme Corporation, 5 Mountain Road, Framingham, Massachusetts 01701 9322, USA
    Nature 444:949-52. 2006
    ..Our results indicate that inhibition of CDK is a new and effective approach to the treatment of PKD...
  14. ncbi request reprint Impaired formation of desmosomal junctions in ADPKD epithelia
    Ryan J Russo
    Genzyme Corporation, 5 Mountain Road, Framingham, MA 01701 9322, USA
    Histochem Cell Biol 124:487-97. 2005
    ..We propose that abnormal expression of PC-1 causes disregulation of cellular adhesion complexes leading to increased proliferation, loss of polarity and, ultimately, cystogenesis...
  15. ncbi request reprint New insights into ADPKD molecular pathways using combination of SAGE and microarray technologies
    Herve Husson
    Functional Genomics, Genzyme Corporation, Framingham, MA 01701 9322, USA
    Genomics 84:497-510. 2004
    ..01. This study may provide valuable insights into the pathophysiology of ADPKD and suggest potential therapeutic targets...
  16. ncbi request reprint Molecular pathogenesis of ADPKD and development of targeted therapeutic options
    Oxana Ibraghimov-Beskrovnaya
    Nephrol Dial Transplant 22:3367-70. 2007
  17. pmc Mechanical stimuli induce cleavage and nuclear translocation of the polycystin-1 C terminus
    Veronique Chauvet
    Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    J Clin Invest 114:1433-43. 2004
    ..Polycystin-2, the product of the second gene mutated in ADPKD, modulates the signaling properties of the polycystin-1 CTT. These data reveal a novel pathway by which polycystin-1 transmits messages directly to the nucleus...
  18. ncbi request reprint Functional analysis of PKD1 transgenic lines reveals a direct role for polycystin-1 in mediating cell-cell adhesion
    Andrew J Streets
    Sheffield Kidney Institute, Division of Clinical Sciences North, University of Sheffield, Clinical Sciences Centre, Northern General Hospital, Herries Road, Sheffield S5 7AU, UK
    J Am Soc Nephrol 14:1804-15. 2003
    ..Disruption of cell-cell adhesion during tubular morphogenesis may be an early initiating event for cyst formation in ADPKD...
  19. ncbi request reprint Cation channel regulation by COOH-terminal cytoplasmic tail of polycystin-1: mutational and functional analysis
    David H Vandorpe
    Molecular Medicine, Beth Israel Deaconess Medical Center, Boston 02215, USA
    Physiol Genomics 8:87-98. 2002
    ..The divalent cation permeability and pharmacological profile of the current has been extended. Inducible expression of the PKD1 fusion in EcR-293 cells was also associated with activation of cation channels and increased Ca2+ entry...